<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        292-186-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PANTONIX 40 mg powder for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>PANTONIX</strong> is a selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine. This medicine is administered into a vein and will only be given to you if your doctor thinks pantoprazole injections or infusions are more suitable for you at the moment than pantoprazole tablets. Tablets will replace your injections or infusions as soon as your doctor sees fit.</p><p style="margin-right:.7pt; text-align:justify"><strong>&nbsp;</strong><strong>PANTONIX</strong> <strong>is used for treating: </strong></p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->Reflux oesophagitis.&nbsp; An inflammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by the regurgitation of stomach acid.</p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->&nbsp;Stomach and duodenal ulcers</p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->Zollinger-Ellison syndrome and other conditions producing too much acid in your stomach</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:.7pt; text-align:justify"><strong>Do not use Pantonix: </strong></p><p style="margin-left:7.1pt; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you are allergic (hypersensitive) to pantoprazole or any of the other ingredients of this medicine (see section 6).</p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you are allergic to medicines containing other proton pump inhibitors.</p><p style="margin-right:.7pt; text-align:justify"><strong>Warnings and precautions </strong></p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you have severe liver problems. Please tell your doctor if you ever had problems with your liver in the past. He will check your liver enzymes more frequently. In case of a rise of liver enzymes the treatment should be stopped.</p><p style="margin-left:7.1pt; margin-right:0cm; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you have reduced body stores or risk factors for reduced vitamin B<sub>12</sub> and receive long-term treatment with<br />pantoprazole. As with all acid reducing agents, pantoprazole may lead to a reduced absorption of vitamin B<sub>12</sub>.</p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you are taking a medicine containing atazanavir (for the treatment of HIV infection) at the same time as pantoprazole, ask your doctor for specific advice.</p><p style="margin-left:7.1pt; margin-right:0cm; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->People who take multiple daily doses of proton pump inhibitor medicines for a long period of time (a year or longer) may &nbsp;&nbsp;have an increased risk of fractures of the hip, wrist or spine. Talk to your doctor about your risk of bone fracture if you &nbsp;&nbsp;take <strong>PANTONIX</strong>.</p><p style="margin-left:7.1pt; margin-right:0cm; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you have low magnesium levels in your body. This problem can be serious. Low magnesium can happen in some people&nbsp; &nbsp;who take proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium.</p><p style="text-align:justify"><strong>Talk to your doctor before taking PANTONIX:</strong></p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you have ever had a skin reaction after treatment with a medicine similar to <strong>PANTONIX</strong> that reduces stomach acid.</p><p style="margin-left:7.1pt; margin-right:.7pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->If you are due to have a specific blood test (Chromogranin A).</p><p style="margin-right:.7pt">If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with <strong>PANTONIX</strong><strong>.</strong></p><p style="margin-right:.7pt">Remember to also mention any other ill-effects like pain in your joints.</p><p style="margin-right:.7pt; text-align:justify"><strong>Tell your doctor immediately </strong>if you notice any of the following symptoms:&nbsp;&nbsp;</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->an unintentional loss of weight</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->vomiting, particularly if repeated&nbsp;</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->difficulty in swallowing or pain when swallowing</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->vomiting blood; this may appear as dark coffee grounds in your vomit</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->you look pale and feel weak (anaemia)</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->you notice blood in your stools, which may be black or tarry in appearance</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->chest pain</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->stomach pain</p><p style="margin-left:36.0pt; margin-right:0cm; text-indent:-36.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp; <!--[endif]-->Severe and/or persistent diarrhoea, as pantoprazole has been associated with a small increase in infectious diarrhoea.</p><p style="margin-right:.7pt; text-align:justify">Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of cancer and could cause delay in diagnosing it.&nbsp; If your symptoms continue in spite of your treatment, further investigations will be considered.</p><p style="margin-right:.7pt; text-align:justify"><strong>Children and adolescents </strong></p><p style="text-align:justify">pantoprazole is not recommended for use in children as it has not been proven to work in children below 18 years of age.</p><p style="margin-right:.7pt; text-align:justify"><strong>Other medicines and </strong><strong>PANTONIX</strong></p><p style="text-align:justify">Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>● &nbsp; Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for<br />&nbsp;&nbsp;&nbsp;&nbsp; certain types of cancer) because pantoprazole may stop these and other medicines from working properly. &nbsp;</p><p>● &nbsp; Warfarin and phenprocoumon, which affect the thickening or thinning of the blood. You may need further checks.</p><p style="text-align:justify">● &nbsp; Atazanavir (used to treat HIV infection).</p><p>● &nbsp; Methotrexate (used to treat rheumatoid arthritis, psoriasis and cancer), if you are taking methotrexate your doctor may<br />&nbsp;&nbsp;&nbsp;&nbsp; temporarily stop your <strong>PANTONIX</strong> treatment because pantoprazole can increase levels of methotrexate in the blood.</p><p style="text-align:justify">In the case of combination therapy, the patient leaflets of the respective medicines should be observed.</p><p style="text-align:justify"><strong>Pregnancy and breast-feeding</strong></p><p style="text-align:justify">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported.&nbsp; You should use this medicine only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby.</p><p style="text-align:justify"><strong>Driving and using machines </strong></p><p style="text-align:justify">If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines.</p><p style="text-align:justify"><strong>Important information about some of ingredient of PANTONIX</strong></p><p style="text-align:justify">This medicine contains sodium.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:.7pt; text-align:justify">Your doctor or nurse will administer the daily dose to you as an injection or infusion into a vein over a period of 2 - 15 minutes.</p><p style="margin-right:.7pt; text-align:justify"><strong>The recommended dose is: </strong></p><p style="margin-right:.7pt; text-align:justify"><strong>Adults - For gastric ulcers, duodenal ulcers and reflux oesophagitis </strong></p><p style="margin-right:.7pt; text-align:justify">One vial (40mg pantoprazole) once a day.</p><p style="margin-right:.7pt; text-align:justify"><strong>For the long-term treatment of Zollinger-Ellison syndrome and other conditions in which too much stomach acid is produced. </strong></p><p style="margin-right:.7pt; text-align:justify">Two vials (80mg pantoprazole) a day.</p><p style="margin-right:.7pt; text-align:justify">Your doctor may later adjust the dose depending on the amount of stomach acid you produce. If you are prescribed more than two vials (80mg) a day, the injections will be in two equal doses. Your doctor may prescribe a temporary dose of more than four vials (160mg) a day. If your stomach acid level needs to be controlled rapidly, a starting dose of 160mg (four vials) should be enough to lower the amount of stomach acid sufficiently.</p><p style="margin-right:.7pt"><strong>Patient with liver problems:</strong></p><p>If you suffer from severe liver problems the daily injections/infusions should be only 20mg (half a vial).</p><p><strong>Use in children and adolescents </strong></p><p>Children (under 18 years): These injections/infusions are not recommended for use in children.</p><p><strong>If you have given too much PANTONIX</strong> <strong>than you should</strong></p><p>These doses are carefully checked by your nurse or doctor so an overdose is extremely unlikely. There are no known symptoms of overdose.</p><p><strong>If you have any further questions on the use of this product ask your doctor, pharmacist or nurse.</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you get any of the following side effects, tell you doctor immediately, or contact the casualty department at your nearest hospital:</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people): </strong></p><p>●&nbsp;&nbsp; Serious allergic reactions: swelling of the tongue and/or throat, difficulty in swallowing, hives (nettle rash), difficulties in<br />&nbsp;&nbsp;&nbsp;&nbsp; breathing, allergic facial swelling (Quincke&rsquo;s oedema / angioedema), severe dizziness with very fast heartbeat and heavy &nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp; sweating.</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>●<strong> &nbsp; Serious skin conditions:</strong> blistering of the skin and rapid deterioration of your general condition, erosion (including slight<br />&nbsp;&nbsp;&nbsp;&nbsp; bleeding) of eyes, nose, mouth/lips or genitals (Stevens-Johnson Syndrome, Lyell Syndrome, Erythema multiforme) and<br />&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light.</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp; Other serious conditions:</strong> yellowing of the skin or the whites of your eyes (severe damage to liver cells,&nbsp; jaundice) or fever,<br />&nbsp;&nbsp;&nbsp;&nbsp; rash and enlarged kidneys sometimes with painful urination and lower back pain (serious inflammation of the kidneys).</p><p><strong>Other side effects are: </strong></p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>●<strong>&nbsp;&nbsp; </strong>Benign polyps in the stomach, inflammation of the wall of the vein and blood clotting (thrombophlebitis) where the<br />&nbsp;&nbsp;&nbsp;&nbsp; medicine is injected.</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><p>●&nbsp;&nbsp; Headache; dizziness;&nbsp; diarrhoea; feeling sick; vomiting; bloating and&nbsp; flatulence (wind); constipation;&nbsp; dry mouth;<br />&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain and discomfort; skin rash; exanthema, eruption; itching; feeling weak;&nbsp; exhausted&nbsp; or generally&nbsp; unwell;<br />&nbsp;&nbsp;&nbsp;&nbsp; sleep disorders. Taking proton pump inhibitor like pantoprazole, especially over period of more than one year, may<br />&nbsp;&nbsp;&nbsp;&nbsp; slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor&nbsp;&nbsp; if you have osteoporosis or if you are<br />&nbsp;&nbsp;&nbsp;&nbsp; taking corticosteroids (which can increase the risk of osteoporosis).</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>●<strong> &nbsp; </strong>Disturbances in vision such as blurred vision;&nbsp; hives; pain in the joints, muscle pains; weight changes; raised body&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp; temperature; swelling&nbsp;&nbsp; of the extremities (peripheral oedema); allergic reactions, depression; breast enlargement in<br />&nbsp;&nbsp;&nbsp;&nbsp; males, distortion or complete lack of sense of&nbsp; taste.</p><p><strong>Very rare (may affect up</strong><strong> </strong><strong>to 1 in 10,000 people):</strong></p><p>●&nbsp;&nbsp; Disorientation.</p><p><strong>Not known</strong> <strong>(frequency cannot be estimated from the available data): </strong></p><p>●<strong> </strong>Hallucination, confusion (especially in patients with a history of these symptoms), decreased sodium level in blood,<br />&nbsp; decreased magnesium level in blood, rash, possibly with pain in the joints, feeling of&nbsp; tingling, prickling, pins and needles,<br />&nbsp; burning sensation or numbness, low levels of potassium which can cause muscle weakness, twitching or abnormal heart<br />&nbsp; rhythm, muscle spasms or cramps, low &nbsp;levels of calcium,&nbsp; inflammation in the large bowel that causes persistent watery<br />&nbsp; diarrhoea.</p><p>&nbsp;If you are on pantoprazole for more than three months it is possible that the levels of magnesium in your blood<br />&nbsp;may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions,<br />&nbsp;dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of<br />&nbsp;magnesium can also lead to a reduction in potassium or calcium levels in the blood.<br />&nbsp;Your doctor may decide to perform regular blood tests to monitor your levels of magnesium (see section 2).</p><p><strong>Side effects identified through blood tests: </strong></p><p>●<strong>&nbsp;&nbsp; Uncommon (may affect up to 1 in 100 people):</strong> An increase in liver enzymes.</p><p>●<strong> &nbsp; Rare (may affect up to 1 in 1,000 people):</strong> An increase in bilirubin; increased fats in the blood;<br />&nbsp;&nbsp; &nbsp;&nbsp;sharp drop in circulating granular white blood cells, associated with high fever.</p><p>●<strong> &nbsp; Very rare (may affect up to 1 in 10,000 people):</strong> A reduction in the number of blood platelets, which may cause you to<br />&nbsp;&nbsp;&nbsp;&nbsp; bleed or bruise more than&nbsp; normal; a reduction in white blood cells which may lead to more frequent infections; coexisting<br />&nbsp;&nbsp;&nbsp;&nbsp; abnormal reduction in the number of red&nbsp; and white blood cells, as well as platelets.<strong> </strong></p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p style="margin-left:18.0pt; margin-right:0cm; text-indent:-18.0pt">●<strong> &nbsp; Saudi Arabia:</strong></p><p style="margin-left:18.0pt; margin-right:0cm; text-indent:-18.0pt"><strong>&nbsp; &nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre:</strong> 19999</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; Website: </strong>https://ade.sfda.gov.sa/</p><p style="margin-left:18.0pt; margin-right:0cm; text-indent:-18.0pt">●<strong> &nbsp; Other GCC States:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p style="text-align:justify"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Keep out of the reach and sight of children.</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Do not use PANTONIX after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of the month.</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Before reconstitution, store below 30&deg;C, protected from light.</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->After reconstitution and dilution, the prepared solution may be stored for up to 12 hours at a temperature below 30&deg;C. Prepared solution must not be frozen.</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Do not use PANTONIX if you notice that the visual appearance has changed (e.g. if cloudiness or precipitation is observed).</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What PANTONIX contains</p><p style="margin-right:.7pt; text-align:justify">The active substance is pantoprazole. Each vial contains Lyophilized (freeze-dried)<em> </em>pantoprazole sodium sesquihydrate equivalent to pantoprazole 40mg</p><p style="margin-right:.7pt; text-align:justify">The other ingredient is: Sodium hydroxide, Nitrogen gas and Water for injection.</p><p style="text-align:justify"><strong>What is the available pack of </strong><strong>PANTONIX?</strong></p><p style="margin-left:0cm; margin-right:0cm"><strong>PANTONIX</strong> Sterile lyophilized powder<strong> </strong>is available in a pack of 1 vial.</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ------------------------------------------------------------------------------------------------------</p><p style="text-align:center"><strong>The following information is intended for medical or healthcare professionals only:</strong></p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">A ready-to-use solution is prepared by injecting 10mL of 0.9% sodium chloride solution for injection or 5% Dextrose solution for injection into the vial containing the dry powder.</p><p style="text-align:justify">This solution may be administered directly or after mixing it with 100mL 0.9% sodium chloride solution for injection or 5% dextrose solution for injection.</p><p style="text-align:justify">The appearance of the product after reconstitution is a clear colourless solution. Do not use if any particles are present in the reconstituted solution.</p><p style="text-align:justify"><strong>PANTONIX</strong> should not be prepared or mixed with solvents other than those stated.</p><p style="text-align:justify">The reconstituted solution of 40mg/10mL is stable for 12 hours at a temperature below 30&ordm;C.</p><p style="text-align:justify">Chemical and physical in-use stability has been demonstrated for 12 hours at a temperature below 30&ordm;C after dilution with 0.9% sodium chloride solution for injection and 5% dextrose solution for injection.</p><p style="text-align:justify">The diluted solutions with 0.9% sodium chloride solution for injection and 5% dextrose solution for injection at concentrations of 80 and 160mg doses should be administered within the infusion time of 15 minutes.</p><p style="text-align:justify">From a microbiological point of view, the product should be used immediately.</p><p style="text-align:justify">The medicine should be administered intravenously over 2 - 15 minutes.</p><p style="text-align:justify">Any product that has remained in the container must be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pantonix Sterile lyophilized powder is available in a pack of 1 vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/06/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>بانتونكس</strong> هو مثبط انتقائي لمضخة البروتون، كما يعمل على تقليل كمية الحامض التي يتم إفرازه في المعدة. يستخدم <strong>بانتونكس</strong> لعلاج أمراض المعدة والأمعاء التي لها صلة بإفراز حامض المعدة. يتم إعطاء هذا الدواء عن طريق الحقن في الوريد أو التسريب الوريدي وسوف يتم إعطائك هذا الدواء في حال اعتقد طبيبك بأن إعطاء حقن بانتوبرازول في هذا الوقت هي الأنسب لك من تناول أقراص بانتوبرازول. وسوف يقوم طبيبك باستبدال حقن بانتوبرازول بأقراص بانتوبرازول في أسرع وقت عندما يقرر طبيبك المعالج الأنسب لحالتك الصحية.&nbsp;</p><p dir="RTL"><strong>يستعمل&nbsp; في علاج الحالات الآتية:</strong></p><p dir="RTL">●<strong> &nbsp; </strong>التهاب المريء الإرتجاعي. وهو التهاب في المريء (القناة التي تصل بين الحلق والمعدة) يصاحبه ارتداد لحامض المعدة.</p><p dir="RTL">● &nbsp; قرحة المعدة والإثني عشري.</p><p dir="RTL">● &nbsp; متلازمة زولينجر - اليسون والحالات المرضية الأخرى التي يزداد فيها إفراز حامض المعدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم استعمال بانتونكس في الحالات التالية: </strong></p><p dir="RTL">●<strong> &nbsp; </strong>إذا كنت تعاني من الحساسية (فرط الحساسية) تجاه بانتوبرازول أو أياً من المكونات الأخرى في هذا الدواء &nbsp;(انظر البند رقم 6).</p><p dir="RTL">●<strong>&nbsp;&nbsp; </strong>إذا كنت تعاني من الحساسية تجاه الأدوية التي تحتوي على إحدى مثبطات مضخة البروتون الأخرى.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">●<strong> &nbsp; </strong>إذا كنت تعاني من مشاكل شديدة في الكبد. يرجى منك إخبار طبيبك المعالج إذا عانيت مسبقاً من مشاكل في الكبد، في هذه الحالة سوف يقوم طبيبك المعالج<br />&nbsp;&nbsp;&nbsp; بإجراء فحوصات لإنزيمات الكبد&nbsp; بشكل متكرر. في حال ارتفاع إنزيمات الكبد، فإنه يجب التوقف عن إعطاء هذا الدواء.</p><p dir="RTL">●&nbsp; <strong>&nbsp;</strong>إذا كنت تعاني من نقص مخزون الجسم&nbsp; لفيتامين ب<sub>12</sub> أو لديك عوامل خطر قد تؤدي إلى نقص فيتامين ب<sub>12</sub> وكنت تتلقى العلاج باستخدام بانتوبرازول<br />&nbsp;&nbsp;&nbsp;&nbsp; لفترة زمنية طويلة &nbsp;الأمد. كما هو عليه الحال مع جميع الأدوية التي تعمل على تقليل كمية الحمض، قد يؤدي بانتوبرازول إلى تقليل امتصاص فيتامين ب<sub>12 </sub><br /><sub>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub>في الجسم.<strong> </strong></p><p dir="RTL">●<strong> &nbsp; </strong>إذا كنت تتناول دواء يحتوي على أتازانافير (دواء لعلاج عدوى فيروس نقص المناعة البشرية المكتسبة) في نفس الوقت مع بانتوبرازول، يرجى منك استشارة<br />&nbsp;&nbsp;&nbsp; طبيبك المعالج&nbsp; للحصول على النصيحة.</p><p dir="RTL">●<strong> &nbsp; </strong>قد يكون الأشخاص الذي يتلقون جرعات يومية مزدوجة من مثبطات مضخة البروتون لفترة زمنية طويلة الأمد (سنة أو أكثر) معرضون لزيادة خطر<br />&nbsp;&nbsp;&nbsp; الإصابة بكسور في عظم الورك أو المعصم أو العمود الفقري. يجب عليك التحدث إلى طبيبك المعالج إذا كنت تتلقى العلاج باستخدام <strong>بانتونكس</strong> حول<br />&nbsp;&nbsp;&nbsp; التعرض لخطر الإصابة بكسر العظام.</p><p dir="RTL">●<strong> &nbsp; إ</strong>ذا كنت تعاني من انخفاض في مستويات المغنيسيوم في الجسم. قد يكون ذلك اضطراب خطير. من الممكن أن يحدث انخفاض في مستويات المغنيسيوم لدى<br />&nbsp;&nbsp;&nbsp; بعض الأشخاص الذين يتلقون مثبطات مضخة البروتون لمدة لا تقل عن 3 أشهر. يحدث ذلك عادةً بعد سنة واحدة من تلقي العلاج. قد تعاني أو لا تعاني من<br />&nbsp;&nbsp;&nbsp; أعراض انخفاض مستويات المغنيسيوم.</p><p dir="RTL"><strong>يرجى منك التحدث إلى طبيبك المعالج قبل أن يتم إعطائك بانتونكس:</strong></p><p dir="RTL">●<strong> &nbsp; </strong>إذا عانيت مسبقاً من تفاعلات جلدية بعد تلقي العلاج باستخدام دواء مماثل لدواء <strong>بانتونكس</strong> الذي يعمل على تقليل كمية الحامض في المعدة.</p><p dir="RTL">●<strong> &nbsp; </strong>إذا كنت سوف تقوم بإجراء فحص دم معين (فحص كروموجرانين أ)</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج في أقرب وقت ممكن، في حال حدوث طفح جلدي، وبصفة خاصة&nbsp; في المناطق التي تتعرض لأشعة الشمس، فقد تحتاج إلى التوقف عن العلاج بدواء <strong>بانتونكس.</strong></p><p dir="RTL">كما عليك إخبار الطبيب المعالج حول أية تأثيرات أخرى على سبيل المثال الألم في المفاصل.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج على الفور </strong>إذا لاحظت أياً من الأعراض التالية:</p><p dir="RTL">●<strong> &nbsp; </strong>فقدان الوزن بشكل غير مقصود</p><p dir="RTL">●<strong> &nbsp; </strong>تقيؤ، وبصفة خاصة التقيؤ بشكل متكرر</p><p dir="RTL">● &nbsp; صعوبة في البلع أو الشعور بالألم عند البلع</p><p dir="RTL">● &nbsp; تقيؤ دموي، قد تظهر جزيئات داكنة اللون تشبه حبيبات القهوة</p><p dir="RTL">●<strong> &nbsp; </strong>شحوب لون البشرة والشعور بالضعف (فقر الدم)</p><p dir="RTL">● &nbsp; خروج دم في البراز بشكل ملحوظ، قد يكون البراز أسود قطراني اللون</p><p dir="RTL">● &nbsp; ألم في الصدر</p><p dir="RTL">● &nbsp; ألم في المعدة</p><p dir="RTL">● &nbsp; إسهال شديد و/أو مستمر، فقد يصاحب بانتوبرازول زيادة بسيطة في الإسهال الناتج عن العدوى.</p><p dir="RTL">قد يقرر طبيبك المعالج أنك بحاجة لإجراء بعض الفحوصات لاستبعاد إصابتك بأية أمراض&nbsp; خبيثة، وذلك لأن استعمال بانتوبرازول أيضاً يخفي أعراض السرطان، الأمر الذي يؤدي إلى التأخر في تشخيصها. وفي حال استمرار الأعراض بالرغم من أخذ العلاج، فإنك سوف تخضع لفحوصات أخرى.&nbsp;&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى بإعطاء بانتوبرازول للأطفال، حيث أن لم يتم معرفة مدى سلامة وفعالية استعمال هذا الدواء من قبل الأطفال بعمر أقل من 18 سنة.</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن مع بانتونكس</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتلقى أو تلقيت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية.</p><p dir="RTL">●<strong> &nbsp; </strong>أدوية مثل كيتوكونازول، إتراكونازول وبوساكونازول (يستخدم لعلاج العدوى الفطرية) أو إيرلوتينيب (يستخدم لعلاج أنواع معينة من السرطان) فقد يعيق<br />&nbsp;&nbsp;&nbsp;&nbsp; بانتوبرازول مفعول هذه الأدوية&nbsp; وغيرها من العمل بصورة ملائمة.</p><p dir="RTL">●<strong> &nbsp; </strong>الوارفارين وفينبروكومون، التي تعمل على تمييع الدم. قد تحتاج لإجراء فحوصات إضافية.</p><p dir="RTL">●<strong> &nbsp; </strong>أتازانافير (لعلاج عدوى فيروس نقص المناعة البشرية المكتسبة).</p><p dir="RTL">● &nbsp; ميثوتريكسيت (يستخدم لعلاج التهاب المفاصل الروماتويدي، الصدفية والسرطان) &ndash; قد يتوقف طبيبك المعالج عن إعطائك العلاج باستخدام <strong>بانتونكس</strong><br />&nbsp;&nbsp;&nbsp;&nbsp; بصورة مؤقتة، في حال كنت تتناول ميثوتريكسيت، وذلك نظراً أن بانتوبرازول من الممكن أن يسبب في زيادة مستويات ميثوتريكسيت في الدم.</p><p dir="RTL">في حال تلقي العلاج المشترك، يرجى الرجوع إلى النشرة الدوائية المخصصة للمرضى المرفقة لكل من الأدوية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعاملين معه للحصول على المشورة الطبية قبل أن يتم إعطائك هذا الدواء، إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين بأنك حاملاً أو تخططين لكي تصبحين حاملاً.</p><p dir="RTL">لا توجد معلومات كافية بشأن استعمال بانتوبرازول من قبل النساء الحوامل، وسجلت التقارير بأنه يطرح في حليب الثدي لدى الإنسان.</p><p dir="RTL">يجب أن لا يتم إعطائك هذا الدواء إلا في حال رأى طبيبك المعالج بأن الفوائد المرجوة للأم الحامل تفوق المخاطر المحتمل حدوثها للجنين أو الطفل الرضيع.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب عليك عدم القيادة أو تشغيل الآلات، في حال تعرضك لتأثيرات جانبية على سبيل المثال الدوخة أو اضطراب في الرؤية.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات بانتونكس</strong></p><p dir="RTL">يحتوي هذا الدواء على الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يقوم الطبيب المعالج أو الممرض بإعطائك الجرعة اليومية عن طريق الحقن في الوريد&nbsp; أو التسريب الوريدي خلال فترة زمنية من 2 -&nbsp; 15 دقيقة.</p><p dir="RTL"><strong>يبلغ مقدار الجرعة الموصى بها على النحو الآتي: </strong></p><p dir="RTL"><strong>البالغون - لعلاج قرحة المعدة، قرحة الاثنى عشر، والتهاب المريء الارتجاعي</strong></p><p dir="RTL">زجاجة واحدة (40 ملغم بانتوبرازول) مرة واحدة يومياً.</p><p dir="RTL"><strong>لعلاج متلازمة زولينجر&ndash; اليسون على المدى الطويل وغيرها من حالات فرط إفراز حامض المعدة. </strong></p><p dir="RTL">زجاجتين (80 ملغم بانتوبرازول) يومياً.</p><p dir="RTL">قد يقوم طبيبك المعالج بتعديل جرعة <strong>بانتونكس</strong> اعتماداً على كمية الحامض التي يتم إفرازه في المعدة، وفي حال كان مقرر لك أكثر من زجاجتين (80 ملغم) يومياً، عندئذ يجب تقسيم الحقنة إلى جرعتين متساويتين. كما قد يصف لك طبيبك المعالج جرعة مؤقتة تبلغ أكثر من أربع زجاجات في اليوم (160 ملغم) يومياً. وإذا كان الأمر يتطلب سرعة السيطرة على المستويات المرتفعة من حامض المعدة، فإن إعطاء جرعة ابتدائية مقدارها 160 ملغم (4 زجاجات) تكون كافية لخفض كمية الحامض الزائدة بدرجة مناسبة.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكبد:</strong></p><p dir="RTL">●<strong> &nbsp; </strong>إذا كنت تعاني من مشاكل شديدة في الكبد فيجب أن تكون الجرعة اليومية 20 ملغم فقط (نصف زجاجة) عن طريق الحقن في الوريد أو التسريب الوريدي.</p><p dir="RTL"><strong>الاستعمال من قبل الأطفال والمراهقون</strong></p><p dir="RTL">الأطفال (بعمر أقل من 18 سنة): لا يوصى بإعطاء هذا الدواء للأطفال عن طريق الحقن في الوريد أو التسريب الوريدي.</p><p dir="RTL"><strong>إذا تم إعطائك بانتونكس بجرعة أكثر مما يجب عليك تلقيها</strong></p><p dir="RTL">إن هذه الجرعات تعطى لك بدقة تحت إشراف طبيبك المعالج أو الممرض، لذلك من النادر جداً حدوث فرط للجرعة. لا توجد أعراض معروفة تدل على فرط الجرعة.</p><p><strong>يرجى منك استشارة طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال كان لديك أية أسئلة إضافية حول استعمال هذا الدواء. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يؤدي هذا الدواء إلى حدوث تأثيرات جانبية، على الرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج على الفور، أو اتصل بقسم الطوارئ في أقرب مستشفى لديك، &nbsp;في حال تعرضت لأي من التأثيرات الجانبية التالية:</strong></p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص):</strong></p><p dir="RTL">●<strong> </strong>تفاعلات تحسسية خطيرة: تورم في اللسان و/أو الحلق، صعوبة في البلع، طفح جلدي على شكل خلايا النحل (طفح القراص)، صعوبة في التنفس، تورم في الوجه الناتج عن التحسس (وذمة كوينك/ وذمة وعائية)، دوخة شديدة مصحوبة بتسارع شديد في ضربات القلب وفرط التعرق.</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة):</strong></p><p dir="RTL">●<strong> </strong><strong>تفاعلات جلدية خطيرة: </strong>ظهور تقرحات في البشرة و تدهور سريع في حالتك الصحية، تآكل (بما في ذلك&nbsp; حدوث نزف خفيف) في كلاً من العينين، الأنف، الفم/الشفتين أو الأعضاء التناسلية (متلازمة ستيفنز- جونسون، متلازمة لايل، حمامي متعددة الأشكال) وحساسية تجاه الضوء.</p><p dir="RTL">●<strong> </strong><strong>حالات مرضية خطيرة أخرى:</strong> اصفرار الجلد أو بياض العينين (تلف شديد للخلايا الكبدية، يرقان أو حمى، طفح جلدي وتضخم في الكلى يصاحبه في بعض الأحيان ألم أثناء التبول وألم في أسفل الظهر (التهاب خطير في الكلى).</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى:</strong></p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص): </strong></p><p dir="RTL">● ورم حميد في المعدة، التهاب في جدار الوريد وتخثر الدم (التهاب الوريد الخثاري) في موضع الحقن.</p><p dir="RTL"><strong>غير شائعة </strong>(قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص):</p><p dir="RTL">●<strong> </strong>صداع، دوخة، إسهال، الشعور بالتوعك، تقيؤ، انتفاخ (غازات)، إمساك، جفاف الفم، ألم في البطن والشعور بعدم الراحة، طفح جلدي، طفح مصحوب بحمى،<br />&nbsp;&nbsp; احمرار في الجلد، حكة، الشعور بالضعف، الشعور بإنهاك أو بتوعك عام، اضطرابات في النوم. يؤدي استعمال مثبطات مضخة البروتون على سبيل المثال<br />&nbsp;&nbsp; بانتوبرازول وبصفة خاصة عند استعمالها لفترة زمنية تتجاوز عن سنة واحدة إلى زيادة خطر الإصابة بكسر في عظم الورك أو المعصم أو العمود الفقري<br />&nbsp;&nbsp; بصورة طفيفة. يجب عليك التحدث إلى طبيبك المعالج إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول كورتيكوستيرويدات (التي يمكن أن تزيد من<br />&nbsp;&nbsp; خطر هشاشة العظام).</p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص): </strong></p><p dir="RTL">●<strong> </strong>اضطرابات في الرؤية على سبيل المثال عدم وضوح الرؤية، طفح جلدي على شكل خلايا النحل، ألم في المفاصل، ألم في العضلات، تغيرات في&nbsp; الوزن، ارتفاع درجة حرارة الجسم، تورم في الأطراف (وذمة طرفية)، تفاعلات تحسسية، اكتئاب، تضخم الثدي لدى الرجال، اضطرابات في حاسة &nbsp;التذوق أو فقدانها بشكل تام.</p><p dir="RTL"><strong>نادرة جداً (قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص): </strong></p><p dir="RTL">●<strong> </strong>توهان.</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة):</strong></p><p dir="RTL">● هلوسة، ارتباك (وبصفة خاصة لدى المرضى الذين لديهم تاريخ مسبق لمثل هذه الأعراض)، انخفاض مستويات الصوديوم في الدم، انخفاض مستويات المغنيسيوم في الدم، طفح جلدي الذي من المحتمل أن يكون مصحوباً بألم في المفاصل، الشعور بالوخز كوخز الإبر والدبابيس، الشعور بالحرقة أو &nbsp;&nbsp;التنميل، انخفاض مستويات البوتاسيوم التي تسبب في حدوث ضعف العضلات، الشعور بالوخز أو اضطرابات في نظم ضربات القلب، تقلصات أو<br />&nbsp;تشنجات عضلية، انخفاض مستويات الكالسيوم، التهاب الأمعاء الغليظة التي تسبب في حدوث إسهال مائي بصورة مستمرة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المحتمل أن يؤدي استعمال بانتوبرازول لفترة زمنية أكثر من ثلاثة أشهر إلى انخفاض مستويات المغنيسيوم في الدم. يتمثل انخفاض مستويات المغنيسيوم في الدم على هيئة الشعور بالتعب، تقلصات العضلات اللاإرادية، ارتباك ، تشنجات، الشعور بالدوخة، ارتفاع معدل ضربات القلب. يرجى منك إخبار طبيبك المعالج على الفور، إذا عانيت من أية هذه الأعراض. كما من الممكن أن يؤدي انخفاض المغنيسيوم إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك المعالج بإجراء فحوصات الدم الدورية لمراقبة مستويات المغنيسيوم لديك (انظر البند رقم 2).</p><p dir="RTL"><strong>التأثيرات الجانبية تظهر في فحوصات الدم:</strong></p><p dir="RTL">●<strong> </strong><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص): </strong>ارتفاع في إنزيمات الكبد.</p><p dir="RTL">●<strong> نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص):</strong> ارتفاع مستوى&nbsp; البليروبين، ارتفاع مستوى الدهون في الدم، انخفاض حاد في مستوى<br />&nbsp;&nbsp; خلايا الدم البيضاء المحببة المصحوبة بحدوث حمى&nbsp; مرتفعة.</p><p dir="RTL">●<strong> نادرة جداً (قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص):</strong> انخفاض في تعداد الصفائح الدموية، مما قد يسبب لك زيادة سرعة<br />&nbsp;&nbsp; حدوث النزف أو الكدمات عن المعدل الطبيعي، نقص في عدد خلايا الدم البيضاء، الأمر الذي قد يؤدي إلى تكرار إصابتك بالعدوى، تواجد انخفاض غير<br />&nbsp;&nbsp; طبيعي لتعداد خلايا الدم الحمراء، خلايا الدم البيضاء والصفائح الدموية.</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL">● <strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; </strong><strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; </strong><strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">&nbsp; &nbsp;&nbsp;ا<strong>لموقع الإلكتروني:</strong> /https://ade.sfda.gov.sa</p><p dir="RTL">●<strong> دول الخليج العربي الأخرى:</strong></p><p dir="RTL">&nbsp;&nbsp; الرجاء الاتصال بجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp; </strong>يحفظ بعيداً عن متناول و مرأى الأطفال.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>يجب عدم استعمال <strong>بانتونكس</strong> بعد تاريخ انتهاء الصلاحية المدون بعد كلمة &lsquo;EXP&rsquo; المذكورة على العبوة والزجاجة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.&nbsp;</p><p dir="RTL">&ndash;&nbsp; قبل التحضير، يحفظ&nbsp; في درجة حرارة أقل من 30&deg;م، بعيداً عن الضوء.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>بعد تحضير المحلول وتخفيفه، يمكن حفظ المحلول لمدة تصل إلى 12 ساعة إذا تم حفظه في درجة حرارة 30&deg;م. يجب عدم تجميد المحلول المحضر.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong><strong>وفقاً للرؤية الميكروبيولوجية، يجب استعمال هذا المستحضر فور تحضيره. وفي حال عدم استعماله فور تحضيره، تصبح مدة حفظ الدواء وظروف حفظه مسؤولية المستخدم. </strong></p><p dir="RTL"><strong>&ndash;&nbsp; </strong><strong>يجب عدم استعمال بانتونكس إذا لاحظت تغير في مظهره (على سبيل المثال وجود تلبد أو مواد مترسبة).</strong></p><p>يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;<strong>&nbsp;ما هي محتويات بانتونكس</strong></p><p dir="RTL">&nbsp;المادة الفعالة هي بانتوبرازول. تحتوي كل زجاجة على بانتوبرازول أحادي ونصف هيدرات الصوديوم (مجفف بالتجميد) بما يعادل بانتوبرازول 40 ملغم.</p><p dir="RTL">&nbsp;المكونات الأخرى: هيدروكسيد الصوديوم، غاز النيتروجين وماء معد للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر مسحوق بانتونكس المعقم المجفف بالتجميد في عبوة تحتوي على زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2/6/2021م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pantonix 40mg Powder for Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item no.	Material Name	Scale (mg/Vial)
		
	Active Ingredient:	
1.		Pantoprazole sodium sesquihydrate 	45.10
	Equivalent to Pantoprazole 	40.00
		
	Inactive Ingredients: 	
1.		Water for Injection 	q.s. 
2.		Nitrogen gas	q.s.

Note: 4% NaOH solution may be used for pH adjustment if necessary.

For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile lyophilized powder for preparation of an injection/infusion solution
Description: White to off-white lyophilized powder. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:9.35pt; margin-right:0cm; text-align:justify; text-indent:-9.35pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Reflux oesophagitis</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Gastric and duodenal ulcer</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">This medicine should be administered by a healthcare professional and under appropriate medical supervision.</p><p style="text-align:justify">Intravenous administration of pantoprazole is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with pantoprazole i.v. should be discontinued and 40 mg pantoprazole p.o. should be administered instead.</p><p style="text-align:justify"><strong><u>Posology</u></strong></p><p style="text-align:justify"><strong><u>Gastric and duodenal ulcer, reflux oesophagitis </u></strong></p><p style="text-align:justify">The recommended intravenous dose is one vial of pantoprazole (40 mg pantoprazole) per day.</p><p style="text-align:justify"><strong><u>Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions </u></strong></p><p style="text-align:justify">For the long-term management of Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions patients should start their treatment with a daily dose of 80 mg pantoprazole. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.</p><p style="text-align:justify">In case a rapid acid control is required, a starting dose of 2 x 80 mg pantoprazole is sufficient to manage a decrease of acid output into the target range (&lt;10 mEq/h) within one hour in the majority of patients.</p><p style="text-align:justify"><strong><u>Special populations</u></strong></p><p style="text-align:justify"><strong>Patients with hepatic impairment</strong></p><p style="text-align:justify">A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in patients with severe liver impairment (see section 4.4).</p><p style="text-align:justify"><strong>Patients with renal impairment</strong></p><p style="text-align:justify">No dose adjustment is necessary in patients with impaired renal function.</p><p style="text-align:justify"><strong>Elderly population</strong></p><p style="text-align:justify">No dose adjustment is necessary in elderly patients.</p><p style="text-align:justify"><strong>Paediatric patients</strong></p><p style="text-align:justify">The experience in children is limited. Therefore, pantoprazole i.v. &nbsp;is not recommended for use in patients below 18 years of age until further data become available.</p><p style="text-align:justify"><strong><u>Method of administration</u></strong><strong>:</strong></p><p style="text-align:justify">A ready-to-use solution is prepared in 10mL of 0.9% sodium chloride solution for injection or 5% Dextrose solution for injection. For instructions for preparation see section 6.6.</p><p style="text-align:justify">The prepared solution may be administered directly or may be administered after mixing it with 100mL of 0.9%sodium chloride solution for injection, or 5% dextrose solution for injection.</p><p style="text-align:justify">The solution obtained should be administered within 12 hours (see section 6.3).</p><p style="text-align:justify">The medicinal product should be administered intravenously over 2 &ndash; 15 minutes.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Gastric malignancy</u></strong></p><p style="text-align:justify">Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis. In the presence of any alarm symptom (e. g. significant unintentional weight loss, recurrent vomiting, dysphagia, Nhaematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.</p><p style="text-align:justify">Further investigation is to be considered if symptoms persist despite adequate treatment.</p><p style="text-align:justify"><strong><u>Hepatic Impairment</u></strong></p><p style="text-align:justify">In patients with severe liver impairment, the liver enzymes should be monitored during therapy. In the case of a rise of the liver enzymes, the treatment should be discontinued (see section 4.2).</p><p style="text-align:justify"><strong><u>Co-administration with HIV protease inhibitors</u></strong></p><p style="text-align:justify">Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their bioavailability (see section 4.5).</p><p style="text-align:justify"><strong><u>Combination therapy</u></strong></p><p style="text-align:justify">In the case of combination therapy, the summaries of product characteristics of the respective medicinal products should be observed.</p><p style="text-align:justify"><strong><u>Influence on vitamin B12 absorption</u></strong></p><p style="text-align:justify">In patients with Zollinger-Ellison syndrome and other pathological hyper secretory conditions requiring long-term treatment, pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.</p><p style="text-align:justify"><strong><u>Gastrointestinal infections caused by bacteria</u></strong></p><p style="text-align:justify">Pantoprazole, like all proton pump inhibitors (PPIs), might be expected to increase the counts of bacteria normally present in the upper gastrointestinal tract. Treatment with pantoprazole<strong> </strong>may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella and Campylobacter.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><u>Sodium</u></strong></p><p style="text-align:justify">This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. is essentially &#39;sodium-free&#39;.</p><p style="text-align:justify"><strong><u>Hypomagnesaemia</u></strong></p><p style="text-align:justify">Severe hypomagnesaemia has been reported in patients treated with PPIs like Pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p style="text-align:justify">For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p style="text-align:justify"><strong><u>Bone fractures</u></strong></p><p style="text-align:justify">Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10 40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p style="text-align:justify"><strong><u>Subacute cutaneous lupus erythematosus (SCLE)</u></strong></p><p style="text-align:justify">Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Pantoprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p style="text-align:justify"><strong><u>Interference with laboratory tests</u></strong></p><p style="text-align:justify">Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Pantoprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1).</p><p style="text-align:justify">If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p style="text-align:justify"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Medicinal products with pH dependent absorption pharmacokinetics</u></strong></p><p style="text-align:justify">Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may reduce the absorption of other medicinal products where gastric pH is an important determinant of oral bioavailability, e.g some azole antifungals such as ketoconazole, itraconazole, posaconazole and other medicine as erlotinib.</p><p style="text-align:justify"><strong><u>HIV protease inhibitors</u></strong></p><p style="text-align:justify">Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their bioavailability (see section 4.4).</p><p style="text-align:justify">If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g. virus load) is recommended. A pantoprazole dose of 20 mg per day should not be exceeded. Dosage of the HIV protease inhibitor may need to be adjusted.</p><p style="text-align:justify"><strong><u>Coumarin anticoagulants (phenprocoumon or warfarin)</u></strong></p><p style="text-align:justify">Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenoprocoumon or INR. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenoprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time.</p><p style="text-align:justify"><strong><u>Methotrexate</u></strong></p><p style="text-align:justify">Concomitant use of high dose of methotrexate (e.g. 300 mg) and proton pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.</p><p style="text-align:justify"><strong><u>Other interaction studies</u></strong></p><p style="text-align:justify">Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4.</p><p style="text-align:justify">Interaction studies with drugs also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions.</p><p style="text-align:justify">Results from a range of interaction studies demonstrate that pantoprazole does not effect the metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol) or does not interfere with p-glycoprotein related absorption of digoxin.</p><p style="text-align:justify">There were no interactions with concomitantly administered antacids.</p><p style="text-align:justify">Interaction studies have also been performed administering pantoprazole concomitantly with the respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions were found.</p><p style="text-align:justify"><strong><u>Medicinal products that inhibit or induce CYP2C19</u></strong></p><p style="text-align:justify">Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.</p><p style="text-align:justify">Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (<em>Hypericum perforatum</em>) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems.</p><p>&nbsp;</p><p>&nbsp;<p>&nbsp;</p></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Pregnancy:</u></strong></p><p style="text-align:justify">A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or fetal / neonatal toxicity of pantoprazole 40 mg powder for solution for injection.</p><p style="text-align:justify">Animal studies have shown reproductive toxicity (see section 5.3).</p><p style="text-align:justify">As a precautionary measure, it is preferable to avoid the use of pantoprazole during pregnancy.<strong><u> </u></strong></p><p style="text-align:justify"><strong><u>Breastfeeding:</u></strong></p><p style="text-align:justify">Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to the newborns/infants cannot be excluded. Therefore a decision on whether to discontinue breast-feeding or to discontinue/abstain from pantoprazole therapy should take into account the benefit of breast-feeding for the child, and the benefit of pantoprazole therapy for the woman..</p><p style="text-align:justify"><strong><u>Fertility</u></strong></p><p style="text-align:justify">There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).</p><p>&nbsp;</p><p>&nbsp;<p>&nbsp;</p></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machines.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs). The most commonly reported ADRs is injection site thrombophlebitis. Diarrhoea and headache occurred in approximately 1 % of patients.</p><p style="text-align:justify">The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification:</p><p style="text-align:justify">Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p style="text-align:justify">For all adverse reactions reported from post-marketing experience, it is not possible to apply any Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.</p><p style="text-align:justify">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p style="margin-left:0cm; margin-right:0cm; text-align:justify">Table 1. Adverse reactions with pantoprazole in clinical trials and post-marketing experience</p><table cellspacing="0" cellpadding="0" border="1" style="width:0px"><tbody><tr><td style="vertical-align:top; width:16.28%"><p>Frequency</p></td><td rowspan="2" style="vertical-align:top; width:12.88%"><p>Common</p></td><td rowspan="2" style="vertical-align:top; width:15.5%"><p>Uncommon</p></td><td rowspan="2" style="vertical-align:top; width:17.48%"><p>Rare</p></td><td rowspan="2" style="vertical-align:top; width:19.16%"><p>Very rare</p></td><td rowspan="2" style="vertical-align:top; width:18.68%"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>System Organ Class</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%">&nbsp;</td><td style="vertical-align:top; width:17.48%"><p>Agranulocytosis</p></td><td style="vertical-align:top; width:19.16%"><p>Thrombocytopenia; Leukopenia; Pancytopenia</p></td><td style="vertical-align:top; width:18.68%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Immune System Disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%">&nbsp;</td><td style="vertical-align:top; width:17.48%"><p>Hypersensitivity (including anaphylactic reactions and anaphylactic shock)</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%">&nbsp;</td><td style="vertical-align:top; width:17.48%"><p>Hyperlipidaemias and lipid increases (triglycerides, cholesterol); Weight changes</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Hyponatraemia; Hypomagnesaemia (see section 4.4); Hypocalcaemia<sup>(1)</sup>; Hupokalaemia</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%"><p>Sleep disorder</p></td><td style="vertical-align:top; width:17.48%"><p>Depression (and all aggravations)</p></td><td style="vertical-align:top; width:19.16%"><p>Disorientation (and all aggravations)</p></td><td style="vertical-align:top; width:18.68%"><p>Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%"><p>Headache; Dizziness</p></td><td style="vertical-align:top; width:17.48%"><p>Taste disorders</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Parasthesia</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Eye disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%">&nbsp;</td><td style="vertical-align:top; width:17.48%"><p>Disturbances in vision / blurred vision</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:12.88%"><p>Fundic gland polyps (benign)</p></td><td style="vertical-align:top; width:15.5%"><p>Diarrhoea; Nausea / vomiting; Abdominal distension and bloating; Constipation; Dry mouth; Abdominal pain and discomfort</p></td><td style="vertical-align:top; width:17.48%">&nbsp;</td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Microscopic colitis</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%"><p>Liver enzymes increased (transaminases, &gamma;-GT)</p></td><td style="vertical-align:top; width:17.48%"><p>Bilirubin increased</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Hepatocellular injury; Jaundice; Hepatocellular failure</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%"><p>Rash / exanthema / eruption; Pruritus</p></td><td style="vertical-align:top; width:17.48%"><p>Urticaria; Angioedema</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Stevens-John-son syndrome; Lyell syndrome; Erythema multiform; Photo-sensitivity; Subacute cutaneous lupus erythematosus (see section 4.4).</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td><td style="vertical-align:top; width:17.48%"><p>Arthralgia; Myalgia</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Muscle spasm&nbsp;<sup>(2)</sup></p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%">&nbsp;</td><td style="vertical-align:top; width:17.48%">&nbsp;</td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%"><p>Interstitial nephritis (with possible progression to renal failure)</p></td></tr><tr><td style="vertical-align:top; width:16.28%"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:12.88%">&nbsp;</td><td style="vertical-align:top; width:15.5%">&nbsp;</td><td style="vertical-align:top; width:17.48%"><p>Gynaecomastia</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%">&nbsp;</td></tr><tr><td style="vertical-align:top; width:16.28%"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:12.88%"><p>Injection site thrombophlebitis</p></td><td style="vertical-align:top; width:15.5%"><p>Asthenia, fatigue and malaise</p></td><td style="vertical-align:top; width:17.48%"><p>Body temperature increased; Oedema peripheral</p></td><td style="vertical-align:top; width:19.16%">&nbsp;</td><td style="vertical-align:top; width:18.68%">&nbsp;</td></tr></tbody></table><p><sup>&nbsp;</sup></p><p><sup>(1)</sup>&nbsp;Hypocalcemia in association with hypomagnesemia</p><p><sup>(2)</sup>&nbsp;Muscle spasm as a consequence of electrolyte disturbance.</p><p style="text-align:justify"><strong><u>&nbsp;</u></strong></p><p style="text-align:justify"><strong><u>To report any side effect(s):</u></strong></p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&sect; <!--[endif]--><strong>Saudi Arabia:</strong></p><p style="margin-left:7.1pt; text-align:justify">The National Pharmacovigilance Centre (NPC):</p><p style="margin-left:1.0cm; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->SFDA Call Centre: 19999</p><p style="margin-left:1.0cm; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:1.0cm; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website: https://ade.sfda.gov.sa/</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt"><!--[if !supportLists]-->&sect; <!--[endif]--><strong>Other GCC States: </strong></p><p style="text-align:justify">Please contact the relevant competent authority</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">There are no known symptoms of overdose in man.</p><p style="text-align:justify">Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well tolerated. As pantoprazole is extensively protein bound, it is not readily dialysable.</p><p style="text-align:justify">In case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pharmacotherapeutic group:</strong> Drugs for acid related disorders, Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD). Proton pump inhibitors, ATC code: A02BC02</p><p style="text-align:justify"><strong><u>Mechanism of action</u></strong></p><p style="text-align:justify">Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.</p><p style="text-align:justify"><strong><u>Pharmacodynamic effects</u></strong></p><p style="text-align:justify">Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+- ATPase enzyme, i.e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.</p><p style="text-align:justify"><strong><u>Pharmacodynamic effects</u></strong></p><p style="text-align:justify">The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.</p><p style="text-align:justify">An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies.</p><p style="text-align:justify">During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p style="text-align:justify">Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>General pharmacokinetics</u></strong></p><p style="text-align:justify">Pharmacokinetics does not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole is linear after both oral and intravenous administration.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><u>Distribution</u></strong></p><p style="text-align:justify">Pantoprazole&#39;s serum protein binding is about 98 %. Volume of distribution is about 0.15 l/kg</p><p style="text-align:justify"><strong><u>Biotransformation </u></strong></p><p style="text-align:justify">The substance is almost exclusively metabolized in the liver. The main metabolic pathway is demethylation by CYP2C19 with subsequent sulphate conjugation, other metabolic pathway includes oxidation by CYP3A4.</p><p style="text-align:justify"><strong><u>Elimination</u></strong></p><p style="text-align:justify">Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the parietal cell the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).</p><p style="text-align:justify">Renal elimination represents the major route of excretion (about 80 %) for the metabolites of pantoprazole, the rest is excreted with the faeces. The main metabolite in both the serum and urine is desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of pantoprazole.</p><p style="text-align:justify"><strong><u>Special populations</u></strong></p><p style="text-align:justify"><strong>Poor metabolisers</strong></p><p style="text-align:justify">Approximately 3 % of the European population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalysed by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60 %. These findings have no implications for the posology of pantoprazole.</p><p style="text-align:justify"><strong>Renal impairment</strong></p><p style="text-align:justify">No dose reduction is recommended when pantoprazole is administered to patients with impaired renal function (incl. dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed half-life (2 - 3 h), excretion is still rapid and thus accumulation does not occur.</p><p style="text-align:justify"><strong>Hepatic impairment</strong></p><p style="text-align:justify">Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.</p><p style="text-align:justify"><strong>Older people</strong></p><p style="text-align:justify">A slight increase in AUC and Cmax in elderly volunteers compared with younger counterparts is also not clinically relevant.</p><p style="text-align:justify"><strong>Pediatric population</strong></p><p style="text-align:justify">Following administration of single intravenous doses of 0.8 or 1.6 mg/kg pantoprazole to children aged 2 - 16 years there was no significant association between pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:1.45pt; text-align:justify">Non clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p style="margin-right:1.45pt; text-align:justify">In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the forestomach of rats. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumors was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.</p><p style="margin-right:1.45pt; text-align:justify">A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful effects on the thyroid glands are expected.</p><p style="margin-right:1.45pt; text-align:justify">In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg.</p><p style="margin-right:1.45pt; text-align:justify">Investigations revealed no evidence of impaired fertility or teratogenic effects.</p><p style="margin-right:1.45pt; text-align:justify">Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.</p><p style="margin-right:1.45pt; text-align:justify">Data to evaluate a potential effect on the environment is currently limited (see item 6.6 &ndash; disposal of pantoprazole)</p><p style="margin-right:1.45pt; text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" border="0" style="width:382.5pt"><tbody><tr><td style="vertical-align:top; width:382.5pt"><p style="text-align:justify"><strong><u>Inactive Ingredients: </u></strong></p></td></tr><tr><td style="vertical-align:top; width:382.5pt"><ol><li style="text-align:justify">Water for Injection</li></ol></td></tr><tr><td style="vertical-align:top; width:382.5pt"><ol><li style="text-align:justify">Nitrogen gas</li></ol></td></tr></tbody></table><p style="text-align:justify"><strong>Note:</strong> 4% NaOH solution may be used for pH adjustment if necessary.</p><p style="text-align:justify">&nbsp;</p><p>&nbsp;</p><p>&nbsp;<p>&nbsp;</p></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
The reconstituted solution of 40mg/10mL is stable for a period of 12 hours at a temperature below 30ºC. 
Chemical and physical in-use stability has been demonstrated for 12 hours at a temperature below 30ºC after dilution with 0.9% sodium chloride solution for injection and 5% dextrose solution for injection.
The diluted solutions with 0.9% sodium chloride solution for injection and 5% dextrose solution for injection at concentrations of 80 and 160mg doses should be administered within the infusion time of 15 minutes. 
From a microbiological point of view, the prepared solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Before reconstitution, store below 30&ordm;C, protected from light.</p><p style="text-align:justify">After reconstitution and dilution, the prepared solution may be stored for up to 12 hours at a temperature below 30&deg;C. Prepared solution must not be frozen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Clear glass vial with a printed label, 1 vial packed in a printed carton along with a leaflet.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">A ready-to-use solution is prepared by injecting 10mL 0.9% sodium chloride solution for injection or 5% Dextrose solution for injection into the vial containing the powder.</p><p style="text-align:justify">The appearance of the product after reconstitution is a clear colourless solution. Do not use if any particles are present in the reconstituted solution.</p><p style="text-align:justify">This solution may be administered directly or may be administered after mixing it with 100mL 0.9% sodium chloride solution for injection or 5% Dextrose solution for injection.</p><p style="text-align:justify">The reconstituted solution of 40mg/10mL is stable for a period of 12 hours at a temperature below 30&ordm;C.</p><p style="text-align:justify">Chemical and physical in-use stability has been demonstrated for 12 hours at a temperature below 30&ordm;C after dilution with 0.9% sodium chloride solution for injection and 5% dextrose solution for injection.</p><p style="text-align:justify">The diluted solutions with 0.9% sodium chloride solution for injection and 5% dextrose solution for injection at concentrations of 80 and 160mg doses should be administered within the infusion time of 15 minutes.</p><p style="text-align:justify">From a microbiological point of view, the product should be used immediately (see section 6.3).</p><p style="text-align:justify">Pantoprazole should not be prepared or mixed with solvents other than those stated.</p><p style="text-align:justify">The medicine should be administered intravenously over 2-15 minutes.</p><p>The contents of the vial are for single use only. Any product that has remained in the container should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462

Fax No.:   (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02. June. 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>